According to TipRanks.com, Pantginis is a 4-star analyst with an average return of 5.7% and a 42.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
The the analyst consensus on Pharming Group is currently a Hold rating.
See today’s analyst top recommended stocks >>
Based on Pharming Group’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $11.63 million. In comparison, last year the company had a net profit of $6.24 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema.